Floatz logo

Denosumab

Advanced Solid Tumours

Redx Pharma Ltdmonoclonal_antibodyPhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

29 Active assets in the Advanced Solid Tumours cohort.

Asset / SponsorPhaseRating
Ceralasertib
AstraZeneca
Phase 2BB
Cyclophosphamide
EDDC (Experimental Drug Development Centre), A*STAR Research Entities
Phase 2B
Pembrolizumab
EDDC (Experimental Drug Development Centre), A*STAR Research Entities
Phase 2B
Senaparib
Impact Therapeutics, Inc.
Phase 1/2B
Epirubicin
EDDC (Experimental Drug Development Centre), A*STAR Research Entities
Phase 2B

View all 50 →

Same molecule, other indications

Denosumab is also rated in:

metastatic carcinoma in the boneDormant
BBB
Indicative ·
79 / 100
View asset →
breast carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
castration-resistant prostate carcinomaDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →